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Study of the effects of UVB1 on colorectal cancer  
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Highlights 
►UVB1 induces apoptotic cell death of HCT116 colorectal carcinoma cells. 
►UVB1 inhibits cellular migration and invasion in colorectal carcinoma cell line. 
►UVB1 increases E-cadherin and VDR expression in HCT116 cell line. 
► UVB1 reduces tumour volume of a xenograft murine model of colorectal cancer. 
►UVB1 exhibits greater affinity for the VDR ligand binding domain than calcitriol. 
 
 
 
  
 
 
 
 
 
 
 
ABSTRACT 
Vitamin D has been shown to display a wide variety of antitumour effects, but their 
therapeutic use is limited by its severe side effects. We have designed and synthesized a 
Gemini vitamin D analogue of calcitriol (UVB1) which has shown to display 
antineoplastic effects on different cancer cell lines without causing hypercalcemia. The aim 
of this work has been to investigate, by employing in silico, in vitro, and in vivo assays, 
whether UVB1 inhibits human colorectal carcinoma progression. We demonstrated that 
UVB1 induces apoptotic cell death and retards cellular migration and invasion of HCT116 
colorectal carcinoma cells. Moreover, the analogue reduced the tumour volume in vivo, 
and modulated the expression of Bax, E-cadherin and nuclear β-catenin in tumour animal 
tissues without producing toxic effects. In silico analysis showed that UVB1 exhibits 
greater affinity for the ligand binding domain of vitamin D receptor than calcitriol, and that 
several characteristics in the three-dimensional conformation of VDR may influence the 
biological effects. These results demonstrate that the Gemini vitamin D analogue affects 
the growth of the colorectal cancer and suggest that UVB1 is a potential chemotherapeutic 
agent for treatment of this disease. 
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1. INTRODUCTION  
Vitamin D is a prohormone responsible for maintaining calcium and phosphate 
homeostasis. It is metabolized in the liver and kidney to produce the active form of vitamin 
D, named calcitriol [1]. This active form has been shown to regulate most of the 
capabilities that cancer cells acquire in their progression to a malignant state and metastatic 
dissemination. These capabilities named the “hallmarks of cancer” [2] are: sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, altering 
genome stability, inducing inflammation, reprogramming energy metabolism and evading 
immune destruction [3,4]. Calcitriol regulates these processes either through genomic 
and/or non-genomic pathways [4-6]. The genomic effects produced by calcitriol are 
mediated by the Vitamin D Receptor (VDR), a member of the nuclear receptor family that 
exhibits a ligand-dependent transcriptional regulation [7]. Human VDR, which consists of 
427 amino acids, comprises two core functional domains: the DNA binding domain (DBD) 
and the ligand binding domain (LBD), both connected through a hinge region. The LBD 
region is formed by 12 α helices (H1-H12) and 3 β sheets [8]. Activation of VDR is highly 
dependent on the ability of ligands to produce an allosteric control on the LBD by eliciting 
a conformational modulation of the H12 helix, the so-called functional activated domain 
AF-2 which, in turn, mediates the binding of transcriptional co-modulators, leading to the 
corresponding biological events [9]. As expected, the binding site of VDR agonists is 
located in the proximity of the H12 helix, where crucial intermolecular interactions are 
likely to be established. 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the 
second in females, and ranks as the third leading cause of cancer mortality worldwide 
[10,11]. CRC develops through a multistep process in which normal mucosa first 
transitions to adenomatous polyps and then eventually to invasive carcinoma. 
Approximately 40–50% of patients diagnosed with CRC will develop distant metastases. 
In spite of improved survival of patients with metastatic colorectal cancer by treatment 
with chemotherapy over the last decade [12], it is however necessary to find new targeted 
therapies that block the growth and spread of this cancer type.  
Vitamin D compounds have been shown to modulate CRC initiation and progression, 
interacting with Wnt/β-catenin signaling and the innate immune response [13,14]. 
Nevertheless, the use of calcitriol is restricted by its hypercalciuria and hypercalcemic 
effect at therapeutic doses [15]. This can be putatively overcome by the use of analogues 
that retain the antitumour action but have less calcemic effects. 
We have previously reported the synthesis of a novel Gemini vitamin D analog, named 
UVB1, which has two side chains in C-20 and demonstrates potent antitumour effects over 
a wide panel of tumour cell lines and lacks hypercalcemic activity in mice [16]. In the 
present study, we have investigated, by employing in vitro and in vivo assays, whether 
UVB1 inhibits human colorectal carcinoma progression. By applying state-of-the-art 
molecular modeling techniques we have also studied the intermolecular interaction 
between UVB1 and VDR and the corresponding structural effects on AF-2. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and Reagents  
1,25-dihyroxyvitamin D3 (calcitriol) and UVB1 were reconstituted as previously 
described [16]. Briefly, the compounds were dissolved in 100% HPLC-grade isopropanol 
(vehicle) and stored protected from light at –20°C. The calcitriol and UVB1 concentrations 
were determined by UV spectrophotometry between 200 and 300 nm. Both compounds 
were diluted in the culture medium to reach the required concentrations. The maximal 
concentration of vehicle used in this study had no effect on cell growth, migration and 
invasion.  
2.2. Cell lines  
Biological evaluation of UVB1 was performed in the human HCT116 and HCT116 p53-/- 
colorectal carcinoma cell lines. Cells were maintained at 37°C, 5% CO2 in DMEM 
supplemented with 100 U/ml penicillin, 100 U/ml streptomycin, 4 mM glutamine and 10% 
FBS.  
2.3. Cell Count and Viability Assay  
For the dose - time - course response analysis, the HCT116 cells were plated at a density of 
500 cells/well into 96 multi-well plates in complete medium, and treated with 0.01 to 100 
nM of UVB1 or vehicle. The cells were incubated for 24, 48, 72, 96 and 120 h. Following 
treatments, cellular viability was assessed by the WST-1 colorimetric assay (Roche, 
Argentina). The cells were incubated for 1 h with the tetrazolium salt (4-[3-(4-
Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzenedisulfonate) and the formazan 
product determined by absorbance reading at 440 nm. The reference wavelength was 690 
nm. Then the cells were washed with PBS, trypsinized and suspended in complete medium 
(100 µl) and counted manually using a hemocytometer.  
HCT116 p53-/- cells were seeded into 96 multi-well plates in complete medium, and 
treated with 0.01 to 100 nM of calcitriol, UVB1 or vehicle. The medium was replaced 
every 2 days and the cells were incubated for 120 h. They were then washed with PBS 1X, 
trypsinized and suspended in complete medium (100 µl) and counted manually using a 
hemocytometer. Additionally, the results were checked by the WST-1colorimetric assay. 
2.4. Cell Cycle Analysis by Flow Cytometry 
 For fluorescence-activated cell sorting (FACS) analysis, HCT116 cells were plated at a 
density of 100,000 cells per 100 mm dish in DMEM supplemented with 10% FBS. 
Twenty-four hours after plating, cells were treated with UVB1, calcitriol or vehicle (1 
nM) during 120 h. Then, cells were harvested by trypsinization washed twice with ice-cold 
1X PBS, fixed by 70% ethanol and incubated at -20° C during 24 h. Before flow cytometry 
analysis, the cellular double-stranded nucleic acids were stained with propidium iodine (PI) 
(Roche, 50 μg.ml-1) and RNase A (100 U.ml-1) to degrade double-stranded RNA in PBS 
for 60 min at room temperature. Cell cycle analysis was performed with FACScan flow 
cytometry (Becton Dickinson). Data were analysed using Cell Quest software (Becton 
Dickinson, Heidelberg, Germany). One thousand forward scatter gated events were 
collected per sample.  
2.5. TUNEL assay   
Cells were seeded onto coverslips at a density of 50,000 cells per 35 mm dish and after 24 
h they were treated with UVB1, calcitriol or vehicle (100 nM) during 72 h.  Then the cells 
were fixed with 4 % formaldehyde in PBS for 60 min at room temperature, washed with 
PBS twice for 5 min and incubated with blocking solution (3% H2O2 in methanol) during 
10 min. After that, coverslips were washed with PBS twice for 5 min and coated with 
permeabilisation solution (0.1% Triton X-100 in 0.1% sodium citrate, freshly prepared) 
and the In Situ Cell Death Detection Kit, POD (Roche) was employed to detect apoptotic 
cells. Photographs were taken using an inverted phase microscope NIKON ECLIPSE TE 
2000S. Ten fields per condition were evaluated.  
2.6. Wound-Healing Assay  
HCT116 cells (2.5 x 10
5
) were seeded onto sterile 35 mm plates and allowed to grow until 
a confluent cell monolayer was formed. Wound healing assay was performed as previously 
described [17]. Cells were scratched with 200 µl pipette and then fresh medium containing 
UVB1, calcitriol or vehicle 100 nM was added to each plate. The photographs were taken 
at 0 and 18 h after scratching. Images were recorded with a microscope NIKON ECLIPSE 
TE 2000S. The area of the scratches was quantified using Image J Analysis software.  
2.7. Western blot analysis  
After treating the HCT116 cells with UVB1, calcitriol or vehicle, they were lysed in lysis 
buffer containing 2% TRIS 1M, 1% Triton-X 100, 0.5 M EDTA 0.5 M, 2% sodium 
chloride 1M for 30 min on ice and the protein concentration was determined by Bradford 
assay by using a Jasco V-630 spectrophotometer. Lysates were prepared to examine the 
expression of Bax (N-20, sc-493, 1:100; Santa Cruz Biotechnology), Cyclin D1 (SR4, 
1:1,000; Thermo Scientific), Cyclin E (M-20, sc-481, 1:500; Santa Cruz Biotechnology), 
VDR (1:750; Santa Cruz Biotechnology), E-cadherin (H-108, sc-7870, 1:500; Santa Cruz 
Biotechnology) and β-catenin (H-102, sc-7199, 1:1,000; Santa Cruz Biotechnology). The 
same amount of protein was separated by SDS-PAGE and transferred to PDVF membranes 
(Millipore). Membranes were subsequently blocked for 30 min at room temperature and 
further incubated at 4°C overnight with primary antibodies. Then, membranes were 
washed and incubated with the appropriate HRP-conjugated secondary antibodies (Santa 
Cruz Biotechnology) for 90 min at room temperature. Protein bands were visualized using 
the enhanced chemiluminescence method. Relative protein levels were calculated by 
normalization to the amount of actin protein (C-11, sc-1615, 1:1,000; Santa Cruz 
Biotechnology). Data shown are representative of three independent experiments. 
2.8. Immunofluorescence  
Immunofluorescence (IF) was performed as previously described [17]. Briefly, HCT116 
cells were seeded on glass coverslips in 35 mm petri dishes and cultured until 50% 
confluence. They were treated with UVB1, calcitriol or vehicle for 96 h at 100 nM. After 
treatment, they were washed three times with PBS and fixed with paraformaldehyde (PFA) 
4% in PBS. The cells were then permeabilized with 0.2 % triton in PBS and blocked with 
1% BSA in PBS. Then they were incubated with E-cadherin (1:100, Santa Cruz 
Biotechnology) in 1% BSA in PBS for 1 h. After incubation with the primary antibody, the 
cells were washed with PBS and incubated with anti-rabbit Alexa 566 fluoro-conjugated 
antibodies (Molecular Probes, Invitrogen) for 1 h. Then they were washed and mounted. 
The cell nucleus was stained with DAPI (1:10,000). The cells with expression of E-
cadherin were counted by analysing 10 images randomly for each condition.  
2.9. Animal Model and Treatments  
All animal experiments followed the guidelines of the Committee for the Care and Use of 
Laboratory Animals of the NIH and of the local committee. Twelve animals were used in 
the xenograft model. Male N:NHI (S)- Fox1 
nu 
 mice, 25 g, 10 weeks old were purchased 
from the Facultad de Ciencias Veterinarias (La Plata, Argentina). The animals were housed 
under pathogen-free conditions, in plastic cages, under controlled temperature and 
humidity, with a 12:12 hr light–dark cycle and free access to food and water. Animals were 
acclimatized for at least one week before use. 
The tumour xenograft model was employed to assess antitumour activity of UVB1. 
HCT116 cells (5 × 10
6
) [18] were implanted subcutaneously in the backs of mice. When 
the diameter of tumour mass was 5 mm (approximately seven days following cell 
inoculation), animals were randomized in two groups and injected subcutaneously in the 
backs of mice with UVB1 (n=6) and vehicle (n=6) at 40 µg.kg
-1
 three times a week during 
four weeks. Tumour growth was blindly measured daily with calipers, and tumour volume 
was calculated as π/6×a×b2, where a is the length in millimeters, and b is the width in 
millimeters. At the end animals were sacrificed by cervical dislocation. Tumours were then 
removed, weighed, measured and put into formaldehyde for further hematoxylin and eosin 
(H&E) or immunohistochemical studies. Tumour volume was calculated as π/6×a×b×c, 
where a, b, and c are the three tumour dimensions. 
After tumour paraffin sections were dewaxed, they were rehydrated in a series of ethanol 
dilutions and either stained with H&E or used for immunohistochemical studies. Mitotic 
index was calculated as the number of the mitotic figures observed in 10 fields at a 
magnification of ×400 in the H&E stained slides. Also, the percentage of necrotic cells was 
calculated.  
 
2.10. Immunohistochemical Staining 
 
IHC was performed by using the avidin-biotin complex immunoperoxidase technique. Five 
μm sections of paraffin-embedded specimens were mounted on glass slides, deparaffinized 
with xylene, and rehydrated with graded alcohol. They were incubated for 15 min in 3% 
hydrogen peroxide in ethanol at 96 °C to quench endogenous peroxidase. After washing in 
PBS 1X, the sections were blocked for 30 min in 2% bovine serum albumin (BSA, in PBS 
1X) and then incubated overnight at 4 °C with primary antibodies. After that, they were 
incubated with diluted biotinylated secondary antibody for 30 min and then incubated with 
Vectastain ABC reagent (Vector Laboratories Inc.) for 30 min. Diaminobenzidine/H2O2 
were used as substrates for the immunoperoxidase reaction. They were lightly 
counterstained with Harris Hematoxylin (Zymed Laboratories), dehydrated through graded 
ethanol and xylene, mounted with Permount (Fisher Scientific) for analysis by bright field 
microscopy, and examined under an Olympus microscope (CX31). For negative controls, 
the slides were subjected to the same IHC process omitting the primary antibody. Primary 
antibodies used were goat polyclonal anti-Ki-67 (M-19, sc-7846, dilution 1/100) with 
antigen retrieval, rabbit polyclonal anti-Bax (N-20, sc-493, dilution 1/100), rabbit 
polyclonal ant-E-cadherin (H-108, sc-7870, dilution 1/100) and β-catenin (H-102, sc-7199, 
dilution 1/250) from Santa Cruz Biotechnology.  
Immunostained sections were scored semiquantitatively based upon the proportion of 
tumour cells stained and the staining intensity, using the Immuno-Reactive-Score (IRS) 
system as suggested by Remmele and Stegner [19]. Expression was evaluated as 
previously described [20]. The IRS was calculated as the product of the staining intensity 
(graded as: 0= no, 1= weak, 2= moderate and 3 = strong staining) by the percentage of 
positively stained cells (0 = less than 10% of stained cells, 1 = 11–50% of stained cells, 2 = 
51–80% of stained cells and 3 = more than 80% of stained cells). The mean IRSs for Bax , 
E-cadherin and β-catenin in ten randomly chosen fields of the sample (×400 magnification) 
were determined. Ki-67 expression was calculated by the percentage of positively stained 
cells (0 = less than 10% of stained cells, 1 = 11–50% of stained cells, 2 = 51–80% of 
stained cells and 3 = more than 80% of stained cells). All samples were evaluated and 
scored simultaneously by a pathologist (JA) and two investigators (NG and EA), all of 
them blind to sample information.  
 
2.11. Blood Calcium Levels  
 
Animals were treated with 40 µg.kg
-1
 body weight of UVB1 or vehicle (n= 6 per group). 
Blood samples were collected from mice at the beginning and at the end of the 
experiments. Animals were anesthetized as described previously [17] and capillary tubes 
were used to collect blood from the retro-orbital sinus. Samples were held on ice, 
processed at 4°C, and plasma was separated and stored at –20°C until assayed. 
Approximately 40µl of plasma/mouse was obtained. Calcium concentration was 
determined using Ca-Color Arsenazo III AA kit (Wiener Lab, Argentina), measuring the 
absorbance at 650 nm; the sample calcium concentration was calculated based upon 
calcium standards provided by the manufacturer. Additionally, the hematocrit for each 
mouse was analysed before and following treatments to determine if the mice were 
healthy. General toxicity was assessed by clinical measures, such as weight loss, changes 
in appearance and behavior, lethargy and death. Animal weight was evaluated three times a 
week.  
 
2.12. Liver, Kidney and Spleen Histological Analysis  
 
Dissected livers, kidneys and spleens from animals treated with UVB1 and vehicle were 
fixed in 10% saline formalin during 24 h and gradually dehydrated using serial ethanol 
concentrations of 70%, 90%, and 100%. Dehydrated organs were cleared for two h using 
xylol and then included in paraffin. Sections (5 µm thick) were prepared using a rotary 
microtome (Leica, RM 2155), attached to clean slides and stained with H&E for 
histological examination by an expert pathologist (JA). For each slide, 10 fields at ×100 
and ×400 magnification were analysed. 
  
2.13. Molecular modeling studies  
 
Computational studies were performed using as reference the crystallographic structure of 
the calcitriol-VDR complex (pdb code: 1DB1) [7] previously deposited in the Protein 
Databank [21]. The X-ray receptor model used as template structure for the in silico studies 
was carefully selected among the available X-ray crystal structures taking into account the 
quality, performance and structural validation of deposited structures [22]. From these 
analyses it was concluded that the structure deposited in the Protein Databank by Rochel et 
al. under the code 1DB1, constitutes a sufficiently validated model. Initial structures of 
calcitriol and UVB1 were built using the MarvinSketch software [23], after which 
structural and energetic analyses were performed using the Gaussian03 [24] software in 
order to obtain the minimum energy conformation by applying semiempirical (AM1) and 
ab initio (HF/6-311+G*) methods. 
Molecular docking assays were performed using software packages developed by OpenEye 
Scientific Software. Docking procedures consisted of three sequential stages: a) a ligand 
conformer library generation, which was conducted at an energy threshold of 10 kcal/mol 
using the OMEGA software [25,26], b) the docking runs, which were performed by 
applying a fast rigid exhaustive docking approach as implemented in the FRED3 software 
[27-29] with the ChemGauss3 scoring function being used to evaluate and rank resulting 
docked poses. The lowest energy docked pose was considered for further analyses. Stage 
c) involved three dimensional visualization and intermolecular interactions predictions, 
which were performed using the VIDA [30] and LigPlot+ [31] software packages, 
respectively. 
The AMBER14 software package [32,33] was used to obtain and analyse molecular 
dynamics (MD) trajectories. Atomic charges and molecular parameters corresponding to 
calcitriol and UVB1 were assigned from the GAFF force field [34], while those 
corresponding to the macromolecule were assigned from the AMBER force field 99SB 
[35]. To obtain MD trajectories, the complexes predicted by molecular docking were used 
as initial structures, solvated with a pre-equilibrated TIP3P octahedral box of explicit water 
molecules, and subjected to energy minimization. The minimized systems were heated to 
298 K for 100 ps, using a time step of 2 fs under constant pressure and temperature 
conditions. The SHAKE algorithm was applied to constrain bonds involving hydrogen 
atoms. After concluding the heating phase, an equilibration stage (1 ns) was performed and 
followed by the corresponding production stages (20 ns). Analyses of the MD trajectories 
were carried out using the Cpptraj module of AMBER14, with energetic and per-residue 
decomposition analyses being performed by applying the molecular mechanics 
Poisson−Boltzmann surface area (MM-PBSA) approach as implemented in the 
MMPBSA.py tool [36]. The resulting trajectories were visualized using VMD v.1.9 
software [37].  
In all cases, MD trajectories were obtained using CUDA designed code (pmemd.cuda), 
with computational facilities provided by the  P PU  omputing group at the  acultad de 
Matem tica,  stronom a y   sica (  M  ), Universidad  acional de   rdoba,  rgentina.  
2.14. Statistical Analyses  
GraphPad Prism 5.0 software package was used for all statistical analyses. To establish 
whether or not each parameter group represented a normal distribution, a D’ gostino–
Pearson Omnibus normality test was performed. Viability and flow cytometry data were 
analysed using two way ANOVA with Bonferroni posttest analysis. Wound healing assays, 
invasion assays, TUNEL assay, differences in E-cadherin expression between UVB1, 
calcitriol and vehicle were analysed using one way ANOVA with Bonferroni's Multiple 
Comparison Test. Comparison of the tumour volume in vivo and ex vivo statistical 
significance was evaluated using two way ANOVA with Bonferroni posttest and student's t 
test, respectively. Mitotic index, percentage of necrosis and immunohistochemical staining 
were analysed by the non-parametrical Mann– Whitney U test. Effects on plasma calcium 
levels and hematocrit of the animals were analysed by unpaired t test. A p value <0.05 was 
considered significant. 
 
3. RESULTS 
 
3.1. UVB1 induces apoptotic cell death of HCT116 colorectal carcinoma cells 
To evaluate the effects of the analogue on cellular viability we performed dose- and time-
course response experiments over a total period of 120 h and with 0.01 to 100 nM 
concentrations of UVB1 in human colorectal carcinoma cell line (HCT116). As shown in 
figure 1A we observed a significant reduction in cell number at 96 h with the concentration 
of 100 nM of UVB1. Also, we confirmed our previous results showing that the analogue 
decreases cellular viability at 120 h with 0.1 to 100 nM concentrations [16].  
Since the tumour suppressor p53 is important for the regulation of cellular survival and is 
frequently dysregulated in CRC, we performed similar experiments using the cell line 
H T116 p53−/− which lacks p53 protein. Interestingly, the UVB1 analogue did not affect 
the viability of these cells with any of the doses tested. However, calcitriol maintained its 
effect on reducing cell viability. This suggests that UVB1 effects over cell survival is p53-
dependent whereas calcitriol effects are not. 
To further analyse if the reduction in cell number was due to an effect on cell proliferation 
or cell death, the cell cycle was studied by flow cytometry in HCT116 cells treated with 
UVB1 or calcitriol at 1 nM concentration (IC50) for 120 h and labelled with PI. As depicted 
in figure 1C, UVB1 or calcitriol treatment caused an increase in the percentage of cells in 
sub G0/G1 phase compared to vehicle-treated cells. After UVB1 treatment the percentage 
of cells in sub G0/G1 phase was 50.69 ± 1.22% compared to 10.45 ± 1.675% in the vehicle-
treated cells (*** p< 0.001); this increase of cells in sub G0/G1 phase was accompanied by 
a decrease of cells in G0/G1 population and S phase. Calcitriol induced an increase of cells 
in sub G0/G1 phase with a decrease in G2/M. Of note, UVB1 produced a greater increase of 
cells in sub G0/G1 phase compared to calcitriol (50.69 ± 1.22% vs 17.40 ± 2.48%; p= 
0.0003). Thus, UVB1 is three times more potent than calcitriol to cause HCT116 cell 
death. 
In order to corroborate if this increase in sub G0/G1 population was due to an induction of 
apoptosis, TUNEL assay was performed after 72 h of UVB1 or calcitriol incubation at 100 
nM concentration. As shown in figure 1D the treatment with the analogue produced an 
increase in the percentage of TUNEL positive cells respect to control (9.86 ± 1.01% vs 
7.38 ± 0.38%; p= 0.026) while calcitriol did not produce an increase in TUNEL positive 
cells (7.57 ± 0.45% vs 7.38 ± 0.38%; p> 0.05). 
These results are consistent with both the increase in the protein expression levels of Bax, a 
marker of apoptosis, observed after UVB1 treatment (figure 1E) and the absence of change 
in the cell cycle regulators cyclin D and cyclin E by western blot.  
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Figure 1. Study of the effects of UVB1 or calcitriol on cellular viability and cell cycle of human colorectal 
carcinoma cell lines. A) Dose – Time - course response analysis of UVB1 on cell viability of HCT116 cell 
line. B) Cell viability in HCT116 p53-/- cells after exposed to 0.01-100 nM concentrations of UVB1 or 
calcitriol over 120 h. Viability was expressed as percentage of the vehicle-treated cells. Data points represent 
means ± SEM from three independent assays. * p< 0.05, ** p< 0.01 and *** p< 0.001. C) Flow cytometry 
analysis in HCT116 cell line treated with UVB1 (1 nM; 120 h) and calcitriol (1 nM; 120 h) and stained with 
PI. D) TUNEL assay photomicrographs and its quantification of HCT116 cells treated with vehicle, UVB1 or 
calcitriol (100 nM; 72 h). E) Effect of UVB1 and calcitriol on Bax (100 nM, 96 h), cyclin D and cyclin E (1 
nM; 96 h) by western blotting in HCT116 cell line. 
 
3.2. UVB1 retards cell migration and invasion of HCT116 cell line  
Migration and invasion of tumour cells in the surrounding tissues is an important step in 
cancer progression and calcitriol and its analogues have shown to inhibit these processes in 
various tumour types [3,38]. Hence, we evaluated the effect of UVB1 on cell migration by 
a wound healing assay in the HCT116 cells, comparing the analogue effect with that 
exerted by calcitriol. HTC116 cells were grown to confluence, and following a wound 
production they were treated with the analogue, calcitriol or vehicle at 100 nM over 18 h. 
As shown in figure 2A, UVB1 reduced significantly HCT116 cell migration compared to 
the control cells (wound uncovered area:  UVB1: 69.91 ± 4.51 vs vehicle: 48.66 ± 3.87; p= 
0.003). No differences were found in the rate of migration between cells treated with 
calcitriol or vehicle.  
Then we performed invasion assays using Matrigel-coated transwell inserts to extend the 
studies of UVB1 effects on the invasive potential of human colorectal carcinoma cells. As 
observed in figure 2B, UVB1 and calcitriol treatment significantly reduced the number of 
HCT116 invasive cells when compared with vehicle-treated cells (invasive cell number: 
UVB1: 77.23 ± 2.74, calcitriol: 84.93 ± 1.66 vs vehicle: 107.70 ± 4.21; p< 0.001).  
 
 Figure 2. Evaluation of cellular migration and invasion following UVB1 or calcitriol treatment. A) Wound 
healing assay of the HCT116 cells treated with vehicle, UVB1 or calcitriol (100 nM, 18 h). The cells 
migrating into the scratched area were photographed (x200) and wound area was calculated as a percentage 
of migration. B) Cell invasion assay of the HCT116 cell line treated with vehicle, UVB1 and calcitriol (100 
nM, 18 h). Each bar represents the average of 10 randomly chosen fields. Data are shown as the mean ± SEM 
of three independent experiments. * p< 0.05, ** p< 0.01 and *** p< 0.001.   
 
3.3. UVB1 increases E-cadherin and VDR expression in HCT116 cell line 
Calcitriol and some of its analogues promote epithelial differentiation of human colon 
cancer cells by inducing the expression of E-cadherin and by antagonizing the Wnt/β-
catenin pathway [39]. Additionally, it has been demonstrated that the binding of vitamin D 
receptor (VDR) to β-catenin precludes the formation of transcriptionally active β-catenin / 
T cell transcription factor (TCF) complexes in the cell nucleus [40]. Hence, we evaluated 
the expression of E-cadherin and VDR after the treatment of UVB1 or calcitriol in the 
HCT116 cell line. As shown in figure 3A the expression of E-cadherin was increased after 
UVB1 treatment as compared with vehicle treatment (38.32 ± 0.70 % vs 17.00 ± 5.70 %, 
p= 0.012). This was corroborated by western blot (figure 3B). Calcitriol did not produce 
differences in the expression of E-cadherin when compared with the control (23.01 ± 8.61 
% vs 17.00 ± 5.70 %; p> 0.05). Also, UVB1 produced an increase in VDR expression 
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when compared to control treatment while no changes were observed with calcitriol 
treatment (figure 3B). 
 
 
Figure 3. Study of the effect of UVB1 or calcitriol on E-cadherin and VDR expression. A) E-cadherin 
expression in HCT116 cell line by IF. The cells were treated with UVB1, calcitriol or vehicle over 96 h. Each 
bar represents the average of 10 randomly chosen fields. * p< 0.05. B) E-cadherin and VDR expression by 
western blot. The blots correspond to one representative experiment. The graph shows the densitometry of 
bands. The experiments have been performed three independent times. Protein loading was normalized with 
actin. 
 
3.4. UVB1 reduces the tumour volume in a xenograft murine model of colorectal cancer 
To evaluate the antitumour effects of UVB1 in vivo, we studied the effect of this analogue 
on the primary tumour growth in a HCT116 xenograft animal model. The N:NIH(S)-
Fox1
nu
 mice were treated with UVB1 or vehicle (40 µg.kg
-1
 body weight) during four 
weeks. In figure 4A, the evolution of tumour growth in both groups during the time of drug 
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administration is shown. UVB1 reduced the tumour volume significantly; the ex vivo 
tumour volume of the vehicle group was 2563 ± 703 mm
3
 while that of UVB1 group was 
916 ± 153 mm
3
; p= 0.045 (figure 4B).  
 
 
Figure 4. Tumour growth of HCT116 xenograft animal model following treatment with UVB1. A) In vivo 
tumour volume was calculated with the following equation: (A2 x B) x π/6,  : width; B: length. ** p< 0.01. 
B) Ex vivo tumour volume was calculated with the following equation: A x B x C x π/6, where  , B, and   
are the three tumour dimensions. * p< 0.05. C) Representative images of tumour size in each group.  
 
3.5. Evaluation of the mechanisms involved in the reduction of tumour progression  
Since a decrease in tumour size was observed in the UVB1-treated group of mice in the 
HCT116 xenograft animal model, we decided to investigate the mechanisms underlying 
the tumour growth reduction. We studied the number of mitotic figures and the percentage 
of necrotic cells present in the slides of tumours stained with H&E and the expression of 
Ki-67, Bax, E-cadherin and β-catenin by immunohistochemistry (IHC). As shown in figure 
5, no differences in the number of mitotic figures (figure 5A) and in the percentage of 
necrotic cells (data not shown) were found between tumours of the mice treated with the 
analogue with those treated with vehicle. In concordance with this result, Ki67 expression, 
a marker of proliferation, was similar in both groups (figure 5B). On the contrary, the 
expression of Bax, a marker of apoptosis, was increased in primary tumours of UVB1-
treated compared with vehicle-treated animals (median IRS = 2.10 versus 0.17, 
respectively; p= 0.030; figure 5C).  
Since a relationship between calcitriol and the epithelial to mesenchymal transition was 
recently demonstrated [40-42] and considering that the in vitro results showed that the 
analogue UVB1 reduced cell migration and invasion of HCT116 cell line and modulated 
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E-cadherin levels, we decided to investigate the expression of these proteins in the tumour 
tissues. As shown in figure 5D, UVB1 increases E-cadherin (median IRS = 1.69 versus 
0.97; p= 0.004) and decreases nuclear β-catenin (median IRS = 2.10 versus 0.90; p= 0.015, 
figure 5E) expression in animal tumour tissues. 
  
Figure 5. Analysis of the UVB1 and vehicle primary tumours of the xenograft animal model. Evaluation of 
A) mitotic index by H&E, B) Ki-67, C) Bax, D) E-cadherin and E) nuclear β-catenin expression by IHC in 
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s.c. primary tumours of HCT116 animal model. Immuno-Reactive-Score (IRS) was calculated as the product 
of the staining intensity by the percentage of positively stained cells. Representative micrographs of the 
tissues (×400 and ×1,000 for the inset) and parameter quantifications are shown; * p< 0.05, ** p< 0.01. 
 
3.6. Effects of UVB1 on blood calcium levels, hematocrit and histology of organs of the 
animal model  
We had previously demonstrated that the administration of UVB1 to CF1 and nude mice 
did not produce hypercalcemia or toxic effects whereas calcitriol induced both 
hypercalcemia and the death of the animals during the treatment period [16]. We have now 
extended the analyses of the calcemic effects of the analogue studying a longer period of 
time. For this purpose, we tested the blood calcium levels in plasma obtained from the 
xenograft animal model treated with a 40 µg.kg
-1
 of body weight of UVB1 during 30 days. 
As shown in figure 6A, UVB1 did not produce hypercalcemia. In addition, no changes in 
hematocrit (figure 6B), behaviour and body weight (figure 6C) were found. Furthermore, 
no alterations in animal histology of livers, kidneys and spleens were observed (figure 6D) 
at the end of the period of treatment. 
 
 Figure 6. UVB1 effects on calcemic activity, hematocrit, body weight and histological examination of organs 
of the animal model. A) Plasma calcium levels, B) hematocrit, C) animal weight during the treatment and D) 
histological examination of livers, kidneys and spleens from N:NIH(S)-Fox1nu mice of the xenograft model 
treated with UVB1 and vehicle at the end of the treatment period.  
 
3.7. Binding of UVB1 to VDR: Molecular modeling studies 
As described in the Introduction section, the genomic effects of calcitriol are mediated 
through the VDR. In order to study if the differential antitumour effects observed between 
UVB1 and calcitriol are due to a different interaction of these compounds with the VDR, 
we decided to study the interaction between UVB1 and the VDR LBD at a molecular level 
by applying computational techniques, such as molecular docking, molecular dynamics 
(MD) and free energy of binding analyses. A comparative study between UVB1 and 
calcitriol was performed in the search of intermolecular interaction patterns that may 
justify the above presented experimental observations. 
 
3.7.1. Molecular docking studies  
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The crystal structure of the VDR LBD in complex with calcitriol has been previously 
reported by Rochel et al. [7], and considering that this structure corresponds to the 
bioactive conformation of VDR (i.e. contains an activated AF-2 domain), docking of 
UVB1 was performed on this crystallographic structure. Figure 7 presents the 
intermolecular interactions between calcitriol and VDR in the corresponding crystal 
structure and those interactions identified for UVB1 after molecular docking procedures 
were applied. 
 
 
Figure 7. Molecular docking of UVB1 to crystal structure of the VDR LBD. A) Intermolecular interactions 
between calcitriol and VDR, B) Intermolecular interactions between the analog UVB1 and VDR obtained 
from docking studies and C) Intermolecular interactions with VDR shared between calcitriol and UVB1 
(circles) and unique to UVB1 (plain). 
 
Figure 7A depicts the interactions observed for the calcitriol: VDR complex, in which all 
interactions previously identified as critical for allosteric modulation of VDR were 
observed [7,22]. Interactions exhibiting particular relevance include a network of hydrogen 
bonds involving residues Ser237, Arg274, Ser278, Tyr143, His305 and His397. In 
addition, several Van der Waals interactions are established between calcitriol and residues 
Ser275, Cys288, Leu233, Ile271, Trp286, Ile268, Leu309, Met272 and Leu227 of VDR. 
With the exception of Ile268, all these residues also interacted with UVB1 (Figure 7B), 
while several additional Van der Waals interactions were present for the analogue, 
involving residues Tyr147, Val234, Leu404, Leu230, Leu313, Val300, Tyr401 and Leu414 
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(Figure 7C). These observations demonstrate that UVB1 is able to fit within the VDR 
ligand binding site, establishing homologous interactions to those observed for calcitriol, 
and thus eliciting an allosteric modulation of VDR. 
To further study the affinity of UVB1 for VDR, as well as the structural effects on VDR 
upon UVB1 binding, explicit solvent MD simulations were carried out. Both calcitriol and 
UVB1 remained bound to the LBD throughout the 20 ns of MD trajectory. The overall 
interactions energies of each ligand are presented in Table 1 and Figure 8, respectively. 
 
Table 1. Energetic components calculated for the intermolecular interaction between calcitriol and UVB1 
with VDR. 
Component 
Calcitriol 
(Kcal/mol) 
UVB1 
(Kcal/mol) 
Van der Waals -63.2 -77.6 
Electrostatic -28.5 -24.2 
Gas -91.7 -101.8 
Polar solvation 25.7 29.8 
Non polar salvation -8.4 -10.1 
Total -74.4 -82.1 
Energetic components were calculated by means of explicit solvent MD 
simulations.  
 
As can be seen in Table 1, UVB1 exhibited a lower total interaction energy compared to 
that of calcitriol, indicating its enhanced affinity for the LBD than that of the natural 
ligand. This feature is originated in a higher Van der Waals interaction component 
observed for UVB1. To further analyse the interaction patterns, the per-residue total 
interaction energy profiles as well as the differential affinity between calcitriol and UVB1 
are presented in Figure 8. 
 
 Figure 8. Per-residue intermolecular interaction patterns of UVB1 or calcitriol to VDR. A) Per-residue 
interaction energy decomposition for the calcitriol-VDR interaction, B) per-residue interaction energy 
decomposition for the UVB1-VDR interaction and C) per-residue calcitriol – UVB1 interaction energies 
demonstrating favoured contact points for each ligand. 
 
As can be seen in Figures 8A and B, UVB1 exhibited a per-residue intermolecular 
interaction pattern similar to that of calcitriol, strongly suggesting a homologous binding 
mode of the former compound to the LBD. Figure 8C shows the per residue difference 
between interaction energies calculated for calcitriol and those found for UVB1. As can be 
seen, calcitriol exhibited an enhanced interaction with selected polar residues (Ser237, 
Ser275, Ser278 and Tyr295) compared to UVB1, while this last compound exhibited 
enhanced interactions with both polar (Arg274, Glu277, His305 and His397) and apolar 
(Leu227, Val234, Val300, Ala303, Leu309, Ile310 and Leu404) residues compared to 
calcitriol. As was previously mentioned, the higher binding affinity of UVB1 compared to 
calcitriol is mostly driven by the enhanced interaction with the above mentioned apolar 
residues of the VDR LBD. 
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To this point, the affinity of UVB1 for the VDR LBD was analysed. So, in order to further 
study the structural effects of UVB1 binding on the VDR three-dimensional structure, the 
atomic positional fluctuations (RMSF) were monitored throughout the MD simulation for 
H12, using as reference the initial (activated) crystallographic structure. Previous reports 
dealing with the allosteric activation of VDR have identified the conformational role of 
this loop for maintaining the functional AF-2 domain [7,22].  
As can be seen in Figure 9A, UVB1 was able to maintain a similar conformational 
disposition on H12 as that elicited by calcitriol. This structural observation suggests that 
UVB1 is able to maintain an AF-2 conformation homologous to that observed for 
calcitriol, thus supporting the VDR-mediated antitumour effects of this new compound. 
 
 
Figure 9. Atomic positional fluctuations (RMSF) monitored throughout the MD simulation for loop H12. A) 
RMSF relative to the crystallographic structure calculated for residues comprising H12 of VDR, obtained 
during MD trajectories for calcitriol (black) and UVB1 (red), B) Relative positions of calcitriol (blue) and 
UVB1 (red) to loop H12. C) Difference between the RMSF calculated for calcitriol and UVB1 over the 
whole VDR structure subjected to MD studies.   
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 Finally, RMSF values were calculated for the whole structures corresponding to the 
calcitriol and UVB1 MD trajectories, with the differences in per-residue atomic 
fluctuations being computed (Figure 9C). As can be seen, several residues exhibit 
differences in their positional fluctuations when VDR is complexed with calcitriol or 
UVB1. It is noteworthy that UVB1, when compared to calcitriol, is able to restrict the 
positional fluctuations of two residues of the hinge region (His140 and Val159) and several 
ones corresponding to the LBD (Arg252, His326, Leu378 and Phe406-Cys410). Several 
reports have suggested that the hinge region may participate in facilitating the positioning 
of the LBD and modulate the accessibility of loop H12 for the recruitment of co-regulators 
[43]. Considering that ligands and DNA can act together to fine tune the VDR mediated 
regulation of gene expression [8], further studies may be required to assess if the structural 
features presented in Figure 9C may account for the stronger antitumour properties 
observed for UVB1, and particularly its low hypercalcemic effect.       
   
4. DISCUSSION AND CONCLUSIONS  
CRC is the third most commonly diagnosed cancer in males and the second in females, and 
ranks as the third leading cause of cancer mortality worldwide [10,11]. In an effort to 
better understand the molecular dysregulation that lead to the disease, CRC has recently 
undergone extensive molecular characterization. This characterization has revealed 
important oncogenes (e.g., KRAS, BRAF, PIK3CA), tumour suppressor genes (e.g., APC, 
TP53, PTEN) and signaling pathways that are critical for the development, survival, and 
progression of CRC cells. These genes are involved in major signaling pathways that have 
been linked to cancer, including the Wnt/β-catenin, MAPK, TGF-β and PI3K pathways 
[44]. Thus, agents that target these pathways have consequently been developed. However, 
patients who are characterized based on these molecular markers still show remarkable 
variability in terms of prognosis and response to therapy [45]. Therefore, many studies 
have addressed further sub-classifications of CRC, focusing on epigenetic factors and gene 
expression profiles [46,47]. This, in turn, has led to the search of new drugs which might 
contribute to individualized therapy. 
The role of vitamin D in the prevention of colon cancers has been documented [6,48,49]. 
However, the use of vitamin D compounds in clinical trials for the treatment of 
malignancies is limited because of the hypercalcemia resulting from the required 
therapeutic doses [50,51]. Several analogues have been designed, synthesized and tested 
with the aim of obtaining a less hypercalcemic response while retaining their 
chemopreventive properties. We had previously demonstrated that the novel Gemini 
analogue of calcitriol UVB1 exerts considerable antitumour activity in various cell lines 
corresponding to different cancer types, while lacking hypercalcemic or toxic effects in 
mice [16]. In this work we have focused on the antitumour effects of this analogue in CRC. 
Interestingly, UVB1 decreased the tumour growth in the HCT116 xenograft animal model 
of colorectal cancer. This result was expected in light of our in vitro results which showed 
that UVB1 decreases the viability of HCT116 cancer cell line through induction of 
apoptotic cell death and differentiation (increase in E-cadherin) of carcinoma cells. This is 
in accordance with published data showing that apoptosis sensitization by calcitriol in 
colorectal adenoma and carcinoma cells involves the up-regulation of pro-apoptotic 
proteins [52,53].  
Calcitriol is a well-known pro-differentiating hormone which regulates the activity of 
genes involved in cell differentiation. For example, in SW480 colon carcinoma cells, 
calcitriol promotes differentiation by inhibiting β-catenin signaling and inducing the 
expression of adhesion proteins such as E-cadherin, occludin, and vinculin [40]. We have 
demonstrated that the analogue UVB1 up-regulates VDR in vitro, increases E-cadherin 
both in vitro and in animal tissues and decreases nuclear β-catenin in primary tumours of 
UVB1-treated animals. These results are coincident with the mechanisms cited by Palmer 
and col. [40]: the binding of vitamin D receptor (VDR) to β-catenin precludes the 
formation of transcriptionally active β-catenin / T cell transcription factor (TCF) 
complexes in the cell nucleus, thus impairing gene expression and producing β-catenin re-
localization at plasma-membrane adherent junctions as a consequence of calcitriol induced 
E-cadherin upregulation.  
Calcitriol and its analogues appear as promising candidates for colon cancer treatment 
[6,54]. In colorectal cancer cell lines, VDR expression levels decrease with advanced 
stages of the disease [54]. Therefore it is important to identify therapeutic candidates that 
increase VDR expression. In this regard, our results demonstrated a greater up-regulation 
of VDR with UVB1 than with calcitriol treatment. Moreover, our in silico studies of the 
interaction between UVB1 and VDR at the molecular level demonstrated that UVB1 is not 
only able to bind to the VDR ligand binding site, but also exhibits an enhanced affinity 
compared to that of calcitriol. Also, MD simulations were able to further explore the 
structural effects of calcitriol and UVB1 on the three dimensional conformation of VDR, 
identifying several particularities for the new synthetic analog, which may constitute an 
important structure-property relationship for the design of new calcitriol analogs with safe 
antitumour properties. 
Related to this, there are several reports that analyzed the conformations induced in VDR 
by analogues of calcitriol, coactivator interactions and gene transcription. With regard to 
gemini analogues,  orman and col [55] reported a gemini analogue (1α,25-dihydroxy-21-
(3-hydroxy-3-methylbutyl)vitamin D3) which binds less efficiently to VDR (38% 
compared to calcitriol), generates unique conformational VDR changes, stimulates gene 
transcription in ROS cells and inhibits clonal growth with similar or increased potency 
than calcitriol, depending on the cell line studied. In concordance with this, Herdick and 
col [56] demonstrated that the characterization of functional conformations of a nuclear 
receptor, such as the VDR after binding to various analogues, is insufficient for 
extrapolating their gene regulatory potential. They reported a gemini analog (Ro27–2310) 
that behaves in solution assays as a weak VDR agonist in mediating a interaction of VDR 
with any of the three coactivators of the SRC-coactivator family (SRC-1, TIF2, and RAC3) 
and then, in reporter gene or mammalian one-hybrid assays, has a higher potency than 
calcitriol. Most VDR ligands have been identified as agonists or pure or partial antagonists. 
Calberg and col [57] reported that gemini analogues can switch from an inverse agonist to 
a superagonist, when the cells are exposed to high coactivator levels. In this regard, Huet 
and col [58] have shown that the two analogues Gemini-0072 and Gemini-0097 induce an 
extra cavity within the VDR, recruit coactivator SRC-1 better than the parental gemini and 
act as VDR superagonists.  
Taking into account that cell systems differ in their endogenous coactivator expression 
levels [57,59], it would be important the evaluation of the affinity of the tested analogue to 
VDR, transactivation potency and the antitumour effects in the same cell type in order to 
correlate the in silico, in vitro and in vivo effects. Future experiments are aimed at testing 
these activities of UVB1 analogue in HCT116 colorectal cells. 
 
 In conclusion, the effects of UVB1 on controlling the growth of colorectal carcinomas are, 
at least in part, a result of an increase in p53-dependent apoptosis and an induction of 
differentiation. Furthermore, the inhibition of cell migration and invasion observed in vitro 
suggests that this calcitriol analogue may also have antimetastatic effects. Altogether these 
results and those demonstrating lack of hypercalcemic and other toxic effects suggest that 
UVB1 is a potentially effective chemotherapeutic agent for the treatment of colorectal 
carcinomas.  
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